Vaccination of chronic myeloid leukemia patients with autologous in vitro cultured leukemic dendritic cells [7]

Leukemia

Volumn 17, Issue 7, 2003, Pages 1424-1426

  Ossenkoppele, G J ^a   Stam, A G M ^a   Westers, T M ^a   de Gruijl, T D ^a   Janssen, J J W M ^a   van de Loosdrecht, A A ^a   Scheper, R J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; BCR ABL PROTEIN; CANCER VACCINE; CD4 ANTIGEN; CD40 ANTIGEN; CD83 ANTIGEN; CD86 ANTIGEN; CYTARABINE; GAMMA INTERFERON; HYDROXYUREA; IMATINIB; INTERCELLULAR ADHESION MOLECULE 1; INTERFERON;

ADULT; CANCER IMMUNOTHERAPY; CASE REPORT; CELL COUNT; CELL ISOLATION; CELL STRUCTURE; CELL TRANSPLANTATION; CELL VIABILITY; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOKINE RELEASE; DELAYED HYPERSENSITIVITY; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHEMA; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IMMUNE RESPONSE; IN VITRO STUDY; INTERFERON PRODUCTION; LETTER; LEUKEMIA CELL; MALE; MEMORY CELL; PAIN; PHENOTYPE; PRIORITY JOURNAL; SKIN INDURATION; SKIN TEST; SKIN ULCER; TREATMENT OUTCOME; VACCINATION;

EID: 0037586467     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402979     Document Type: Letter

References (12)

1. Clift RA, Appelbaum FR, Thomas ED: Treatment of chronic myeloid leukemia by marrow transplantation. Blood 1993; 82: 1954-1956.
2. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Bone Marrow Transplantation Working Party Chronic Leukemia. Blood 1995; 86: 2041-2050.
3. Coleman S, Throp D, Fisher J, Bailey-Wood R, Lim SH. Cytokine enhancement of immunogenecity in chronic myeloid leukemia. Leukemia 1997; 11: 2055-2059.
4. Clark RE, Dody IA, Hill SC, Lill JR, Aubert G, Macintyre AR et al. Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein. Blood 2001; 98: 2887-2893.
5. Cella M, Sallusto F, Lanzavecchia A. Origin, maturation and antigen presenting function of dendritic cells. Curr Opin Immunol 1997; 9: 10-16.
6. Choudhury A, Gajewski JL, Liang JC, Popat U, Claxton DF, Kliche K-O et al. Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against philadelphia chromosome-positive chronic myelogenous leukemia. Blood 1997; 89: 1133-1142.
7. Vermorken JB, Claessen AME, van Tinteren H, Gall HE, Ezinga R, Meijer S et al. Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet 1999; 353: 345-350.
8. Vuylsteke R JCLM, van Leeuwen PAM, Meijer S, Wijnands PG, Statius Muller MG, Bus DH et al. A novel method of sampling tumor draining lymph nodes for phenotypic and functional analysis of dendritic cells and T-cells. Am J Pathol 2002; 61: 19-26.
9. de Gruijl TD, Bontkes HJ, Walboomers JMM, Stukart MJ, Robbesom AA, vonBlomberg-van der Flier BM et al. Analysis of IgG reactivity against human papillomavirus type-16 E7 in patients with cervical intraepithelial neoplasia indicates an association with clearance of viral infection: results of a prospective study. Int J Cancer 1996; 731: 731-738.
10. Druker BJ, Talpaz M, Resta D, Resta DJ, Peng B, Buchdunger E et al. Activity and safety of a specific inhibitor of the BCR-ABL tyrosine-kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1038-1042.
11. Weisberg E, Griffin JD. Mechanism of resistance to the ABL tyrosine-kinase inhibitor STI571 in BCR-ABL transformed hematopoietic cell lines. Blood 2000; 95: 3498-3505.
12. Tipping AJ, Mahon FX, Zafirides G, Lagarde V, Goldman JM, Melo JV. Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs. Leukemia 2002; 16: 2349-2357.